Refractory and infected pyoderma gangrenosum in a patient with ulcerative colitis: Response to infliximab [5]

Inflammatory Bowel Diseases

Volumn 13, Issue 4, 2007, Pages 509-510

  Martín, F De La Morena L ^a   Gisbert, J P ^a   Goiriz, J Ferná Herrera R ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THALIDOMIDE;

ADULT; BIOPSY; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE ASSOCIATION; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; LETTER; MALE; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; SEPSIS; SKIN DEFECT; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADULT; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; HUMANS; MALE; PYODERMA GANGRENOSUM;

EID: 34247562657     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20081     Document Type: Letter

References (8)

1. Callen JP. Pyoderma gangrenosum. Lancet. 1998;351:581-585.
2. Reichrath J, Bens G, Bonowitz A, et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53:273-283.
3. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
6. Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98:1821-1826.
7. Romero-Gomez M, Sanchez-Munoz D. Infliximab induces remission of pyoderma gangrenosum. Eur J Gastroenterol Hepatol. 2002;14:907.
8. Brooklyn TN, Dunnill GS, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double-blind placebo-controlled trial. Gut. 2006;55:505-509.